a b s t r a c t DMSO has a widespread use as a vehicle for water-insoluble therapeutic drug candidates but may also exert disease-relevant pharmacological effects by itself. However, its influence on the CNS has hardly been addressed. Here we examined the brain structure and function following chronic exposure to low DMSO dose at a paradigm with flawed synaptic connectivity in a preclinical transgenic mouse model for Alzheimer's disease (APP SDL mice). DMSO treatment increased spine density in a region-specific manner in the hippocampus of APP SDL mice ex vivo and in vivo. Moreover, DMSO exhibited clear influence on the behavior of this mouse line by enhancing hippocampal-dependent spatial memory accuracy, modulating hippocampal-independent olfactory habituation and displaying anxiolytic effect. Despite that most of the action of DMSO was observed in animals with elevated Ab levels, the drug did not exert its function via decreasing the oligomeric Ab species. However, challenging organotypic hippocampal slice cultures with NMDA receptor antagonist MK-801 recapitulated the effect of DMSO on spine density, indicating a tuning influence of DMSO on receptor signalization. Our findings demonstrate that DMSO should be considered as a true bioactive compound, which has the potential to be a beneficial adjuvant to counteract Abmediated synaptotoxicity and behavioral impairment.
Dimethyl sulfoxide (DMSO) is widely used in preclinical and clinical research, as it enhances the entrance of water-insoluble drug candidates into the central nervous system (Broadwell et al., 1982) . An ideal vehicle is expected to be biocompatible, reliable, and devoid of biological actions per se. However, within the last decades, pharmacological effects of DMSO have been reported, and some of its biological activities have shown to be beneficial against various pathologies (Santos et al., 2003; Yu and Quinn, 1994) .
As for many pharmaceutical compounds, the mechanism of action of DMSO appears to be dependent of both the treatment duration and the dose employed. While a consensus exists that DMSO doses of 10% or higher are toxic in vivo (Hanslick et al., 2009) , the effects of low DMSO doses both in vitro (Hanslick et al., 2009; Kahler, 2000) and in vivo are still controversially judged (Galvao et al., 2014) . Intriguingly, particularly low DMSO concentrations appear to profoundly influence neural network activities (Nakahiro et al., 1992; Nasrallah et al., 2008; Obregon et al., 2005; Tamagnini et al., 2014; Tsvyetlynska et al., 2005) . Moreover, chronic DMSO treatment has been shown to attenuate spatial memory deficits induced by ischemia (Farkas et al., 2004) suggesting that prolonged DMSO administration has protective actions for the central nervous system (CNS) under pathological conditions. Memory deficits have also been associated with abnormal Ab levels in humans as well as in transgenic mice mimicking amyloidosis-related disorders (Brouillette et al., 2012; Lesne et al., 2006; Shankar et al., 2008) . Synaptic failure is considered to be the immediate cause of cognitive decline and memory dysfunction in Alzheimer's disease (AD) (Dorostkar et al., 2015) . Dendritic spines are anatomical substrates for memory storage ) and spine loss represents an early feature of AD (Penazzi et al., 2016; Selkoe, 2002) , occurring long before the pathological plaque deposition of Ab. Previous studies showed that NMDA receptors (NMDARs) are involved in Ab-mediated synaptic deficits (Lacor et al., 2007; Shankar et al., 2007) and a drug acting as NMDAR antagonist is currently used to attenuate clinical symptoms during mild cognitive impairment (MCI) (Emre et al., 2010) . Elevated Ab levels further correlate with anxiety-like behavior (Lee et al., 2004; Porter et al., 2003) or atypical olfactory-behavior (Alvarado-Martinez et al., 2013; Cheng et al., 2013; Wesson et al., 2010) . These pathological phenotypes represent also relevant criteria for the early diagnosis of neuropathology, such as AD or Parkinson's disease (PD) (Baba et al., 2012; Berendse and Ponsen, 2006; Jimbo et al., 2011) .
To date, only anxiolytic effects of DMSO have been reported (Matheus et al., 1997) but effects on memory have not been studied. Therefore the present study was designed to determine the potential effect of chronic, low, non-toxic DMSO dose on hippocampal plasticity and hippocampal-dependent behavior, and whether this treatment may be beneficial to rescue Abmediated presymptomatic CNS alterations. We first aimed to analyze the consequence of DMSO (0.01%) treatment on spine density using ex vivo hippocampal slice cultures prepared from APP SDL mice and non-transgenic controls. APP SDL mice are a model for the long prodromal phase of AD, since they develop Ab plaques only after 18 months of age (Blanchard et al., 2003) . Furthermore, using this model, we also determined whether spine modulation by DMSO involves NMDARs. Secondly, we hypothesized that the genotype-and region-specific changes observed ex vivo may also occur in the hippocampus of old male transgenic and non-transgenic mice after a prolonged treatment with a low DMSO (1%) dose. At last, we assessed whether such plastic changes may influence hippocampus-dependent and -independent behavior, as well as basal home cage and spatial memory-induced neuronal activities.
Material and methods

Animals
General health assessment and behavioral testing were carried out on male transgenic APP SDL mice and their wild-type littermates. Mice were 17e18 months old at the start of the testing. In addition, adult 7e8 months old male mice from both genotypes were incorporated into the behavioral assessment to evaluate the behavioral performances of the old mice. For dendritic spine analysis, double heterozygous transgenic EGFP/APP SDL mice were generated by crossing transgenic homozygous EGFP mice (GFP M line) (Feng et al., 2000) with heterozygous APP SDL mice. Mice were individually housed per cage in a sterile room with 12/12-h lightdark cycle. The room was maintained under constant temperature and humidity conditions. Water and food were available ad libitum.
All animal studies were conducted in accordance to National Institutes of Health guidelines and German animal care regulations and approved by the ethical committee on animal care and use of Lower Saxony, Germany.
Drug treatment
Dimethyl sulfoxide (Merck KGaA, Darmstadt, Germany) was provided to mice ad libitum at 1% (v/v), mixed in water. The drug treatment was administrated during 14 days prior behavioral testing and was maintained all along the behavioral procedures, thus ending after 20 days of treatment.
Organotypic hippocampal slice cultures and Sindbis virus infection
Organotypic hippocampal slice cultures were generated from postnatal days 7 (P7) mouse pups (Fig. 1B ) that were cultured, infected with Sindbis virus expressing EGFP, and fixed as previously described Sundermann et al., 2012) . For treated conditions, 0.01% DMSO, 50 mM MK-801 or both (Sigma Aldrich, Munich, Germany) were applied in low-serum Nb-N1 medium. For high-resolution imaging, pyramidal neurons located in the hippocampal regions CA1 and CA3 were selected.
Spine analysis in the mouse brain
After 14 days of treatment mice were transcardially fixed with 4% paraformaldehyde in PBS (w/v). The brains were removed, postfixed overnight at 4 C and then transferred to PBS. Hundred mm thick coronal sections were sliced on an automated vibratome (Leica VT1200S, Leica Biosystems), floating sections were collected, mounted with a Confocal-matrix (Micro-Tech-Lab, Graz, Austria) and coverslipped. For imaging, neurons were randomly selected from the dorsal hippocampus (approximately À1.58 mm from Bregma) for each hippocampal subfield: proximal CA3 (e.g. close to the DG), CA2 and intermediate part of CA1 (Supplemental Fig. S2 ). Borders of the CA regions were defined with the help of the nomenclature by Franklin and Paxinos (Franklin and Paxinos, 2007) and Kohara and collaborators (Kohara et al., 2014) .
Spine imaging and quantification
For both fixed organotypic and mouse brain slices, image acquisition and quantification of EGFP expressing dendritic segments were performed as described earlier (Sundermann et al., 2012; ).
Design and behavioral procedures
To minimize the number of mice used in the experiments, the same set of adult and old male mice from both genotypes were used for all behavioral testing. The testing began with an elevated-plus maze test on day 14, followed by the olfactory behavior test on day 15 and the Barnes maze test that started on day 17 of the DMSO treatment period. Except for mice that did not participate in the behavioral tasks (i.e., home cage condition), mice were daily handled during 14 days, prior to the start of the behavioral procedures, to habituate them to the experimenter blinded to the treatment condition and the genotype of mice.
See Supplementary information for the behavioral procedures in detail.
Immunohistochemistry
c-fos immunohistochemistry was performed on coronal brain sections of 50 mm thickness from 17 to 18 months old wild-type and APP SDL mice that performed the Barnes maze task and from additional mice of both genotypes that did not participate in the task (i.e., home cage, basal condition).
Mouse brain sections were produced from brain tissue blocks neuroanatomically defined as follows: the anterior part of the dorsal hippocampus is between À1.58 mm and À1.74 mm from Bregma; the lateral parietal cortex (LPar) and the retrosplenial granular cortex (RSGc) between À1.46 mm and À2.06 mm.
c-fos imaging and quantification
Quantification of the c-fos positive cell density was performed on every third coronal section using the Machine Learning Based Image Segmentation (MLBIS) method (Penazzi et al., 2014) . See Supplemental information and Supplemental Fig. S3 for details.
Other methods and complementary information
For a detailed description of the methods regarding animal lines, general health assessment, oligomeric Ab amount determination, MTT assay, immunohistochemistry and quantification, see Supplementary information.
Statistical analysis
Statistical analysis was conducted using Statistica software (StatSoft Inc, Tulsa, OK, USA). One-way, factorial and repeatedmeasures ANOVA as well as Student's t-test were used in this study, followed by either post-hoc Fisher's LSD for multiple comparisons, Tukey's test or Newman-Keuls. Detailed information of the test applied is described in Supplementary information. All Decreased spine density on dendritic segments from untreated APP SDL slices was significantly attenuated by DMSO in a region-specific manner, whereas the treatment reduced spine density on dendrites from wild-type mice in both hippocampal regions; CA1 and CA3 regions, n ¼ 5 mice/group. (E) Blockage of NMDAR with the antagonist MK-801 alone or MK-801/DMSO decreased spine density from apical dendritic segments imaged from wild-type neurons located in the CA1 and CA3 regions but specifically increased spine density on dendritic segments from APP SDL neurons located in CA1 region. N ¼ 3e6 mice/group. Numbers in bars represent the number of dendritic segments analyzed in each experimental condition. All values are represented as mean ± S.E.M. *P < 0.05 and ***P < 0.001, (D and E) wild-type versus APP SDL , same experimental condition. #P < 0.05, ##P < 0.01 and ###P < 0.001, significantly decreased compared to untreated, same genotype. þ P < 0.05 and þþþ P < 0.001, significantly increased compared to untreated, same genotype. Factorial ANOVA, post-hoc Fisher's LSD for multiple comparisons. For detailed statistics see Supplementary Tables 1 and 2. results are expressed as mean ± S.E.M. The level of significance is set at P < 0.05.
Results
DMSO modulates dendritic spine density in a genotype-specific manner in ex vivo hippocampal organotypic cultures
We first determined a potential toxic effect of DMSO treatment using a MTT reduction assay, an indicator of cell viability. As a neural model, PC12 cells were exposed to 0.01%, 0.1% or 1% of DMSO during 4 days (Fig. 1A) . MTT conversion was significantly altered at 1% DMSO but not at 0.1% or 0.01% (Fig. 1A, Supplementary Table 1) . To explore the effect of non-toxic dose of DMSO on dendritic spine density, 0.01% DMSO was applied for 4 days to organotypic hippocampal slice cultures from wild-type and APP SDL mice (Fig. 1B) . In the absence of DMSO, spine density was significantly reduced on dendritic segments from neurons of APP SDL mice in both CA1 and CA3 regions ( Fig. 1C and D, left, Supplementary Table 2), in agreement with previous results . DMSO treatment increased spine density in the CA1 region of APP SDL mice and decreased spine density in both hippocampal regions of wildtype mice ( Fig. 1C and D, right, Supplementary Table 2 ). This suggests that chronic, low, non-toxic dose of DMSO modulates spines in a region-and genotype-specific manner, abolishing the differences in hippocampal spine density between APP SDL and wild-type mice ex vivo.
Previous studies reported that DMSO suppresses NMDAinduced ion currents and Ca 2þ influx (Lu and Mattson, 2001) therefore we tested the effect of MK-801, a non-competitive NMDA receptor antagonist on hippocampal spine density of wild-type and APP SDL mice (Fig. 1E , Supplementary Table 2) . Treatment of slice cultures with 50 mM MK-801 during 4 days recapitulated the decrease of spine density in CA1 and CA3 regions of wild-type mice and the increase in spine density in the CA1 region of APP SDL mice, closely mimicking the effect of DMSO. MK-801 together with DMSO did not result in further changes. This finding suggests that DMSO modulates spine density via its action on NMDA receptors.
DMSO treatment modulates hippocampal spine density in a genotype-specific manner in vivo
We next aimed to evaluate whether systemic administration of chronic, low, non-toxic DMSO also influences hippocampal spine density in old (17e18 M) wild-type and APP SDL male mice in vivo. At this age, analysis of hippocampal and neocortical regions from APP SDL brain did not reveal the presence of Ab plaques (data not shown), confirming this mouse line as a presymptomatic AD model. The distinct mossy fiber terminal layer is one of the main anatomical references to identify the CA2 hippocampal subfield. Due to the visibility of the entire mossy fiber tract in the GFP M mouse line (Feng et al., 2000) we could include also the analysis of the CA2 hippocampal pyramidal cells. To rule out a potential toxic effect of chronic DMSO, water intake as well as body and organ weights were measured. Body weight of untreated and treated mice from both genotypes remained stable during the 14 days of treatment (Supplemental Fig. S1A ). Except for the significant difference occurring between untreated and treated wild-type mice in the weight of the right kidney, no further changes were observed in organ weight. Daily water intake of mice from both genotypes was not influenced by DMSO treatment (Supplemental Figs. S1B and C). These data strongly suggest that chronic treatment with 1% DMSO induces neither toxic nor diuretic effects in old mice.
The same DMSO treatment was provided to old (17e18 M) EGFP and EGFP/APP SDL male mice ( Fig. 2A) . Dendritic segments from CA1, CA2 and CA3 pyramidal neurons were imaged in the dorsal hippocampus (Supplemental Fig. S2, Fig. 2B ). In the absence of DMSO, spine density was decreased on dendrites of CA1 and CA2 neurons from EGFP/APP SDL mice compared to control EGFP mice (Fig. 2C,  Supplementary Table 3 ). DMSO treatment did not alter spine density on CA1 neurons but increased spine density on dendrites of CA2 and CA3 neurons of EGFP/APP SDL mice (Fig. 2C, Supplementary  Table 3 ). Therefore paralleling our previous observations from ex vivo cultures, in vivo DMSO treatment results in a region-and genotype-specific spine change that tends to abolish Ab-mediated decrease in spine density. However, the effects of DMSO differ between the two systems. One aspect is that DMSO reduces spine significantly increased spine density on neurons from APP SDL mice in CA2 region and on CA3 neurons compared to their untreated counterpart, n ¼ 5 mice/group. No significant change occurred on APP SDL neurons from CA1 region that displayed reduced spine density compared to wild-type mice under untreated condition. Numbers in bars represent the number of dendritic segments analyzed in each experimental condition. All values are represented as mean ± S.E.M. *P < 0.05, **P < 0.01 and ***P < 0.001, wildtype versus APP SDL , same experimental condition. þ P < 0.05, significantly increased compared to untreated, same genotype. Factorial ANOVA followed by post-hoc Fisher's LSD for multiple comparisons. For detailed statistics see Supplementary Table 3. density on dendrites of control mice ex vivo, whereas in the in vivo experiment, this does not seem to happen. The difference may be caused by the progressive age-related changes of the plastic properties of neurons or the respective treatment conditions.
DMSO treatment tends to improve spatial memory accuracy
Potential consequences of chronic DMSO treatment on hippocampal-dependent spatial memory were tested in old (17e18 M) wild-type and APP SDL mice using the Barnes maze task (Barnes, 1979) . Untreated adult (7e8 M) mice from both genotypes were included as additional reference groups for the evaluation of the performance of old mice. Adult and old mice of both genotypes successfully learned to locate the target hole, as demonstrated by the gradual decrease in spatial errors (Fig. 3A, Supplementary  Table 4 ) and escape latency (Fig. 3B, Supplementary Table 4) . A probe test was conducted one day after the last acquisition day. All mice retrieved the target location, as indicated by their selective preference for the target hole compared to chance level (Fig. 3C,  Supplementary Table 4 ). Adult wild-type and APP SDL mice accurately remembered this position as they visited significantly more the target hole than the immediately adjacent holes. In contrast, old untreated wild-type and APP SDL mice displayed a broader search pattern that extended to the immediately adjacent holes, indicating a non-specific effect of aging on spatial memory accuracy.
Interestingly, drug effect in old mice was close to reach significance (P ¼ 0.08, see Supplementary Table 4 ). Detailed analyses confirmed that DMSO treated APP SDL mice significantly focused their search on the target hole whereas vehicle treated APP SDL mice evenly explored target and neighboring holes. This suggests that DMSO treatment tends to increase spatial memory accuracy in APP SDL mice.
We further examined whether DMSO treatment modulates brain activation during spatial memory retrieval using the neuronal activity marker c-fos (Bullitt, 1990) . Semi-automatic detection and quantification of c-fos-positive cell nuclei (Penazzi et al., 2014 ) (Supplemental Fig. S3 ) was performed in the DG, CA3 and CA1 regions of the dorsal hippocampus and in the lateral parietal (LPar) and retrosplenial granular (RSGc) cortices of untreated and treated old wild-type and APP SDL mice, both in basal home cage condition and after spatial memory retrieval. Under basal condition, APP SDL mice displayed hyperactivated DG and CA1 neurons and reduced neuronal activation in the CA3 region (Fig. 4A, Supplementary  Table 5 ). DMSO treatment normalized this Ab-mediated alteration of basal neuronal activation in CA1 and DG to the level of wild-type mice. In the neocortex, no differences were observed in basal neuronal activation in the regions analyzed. However, DMSO increased neuronal activation in the RSGc of wild-type mice (Fig. 4 B, Supplementary Table 5 ). Taken together, DMSO showed a regionand genotype-specific inhibitory effect on neuronal activation Wild-type mice: þ P < 0.05, þþ P < 0.01 and þþþ P < 0.001, versus day 1; APP SDL mice: $ P < 0.05, $$ P < 0.01 and $$$ P < 0.001, versus day 1. (C) During the probe trial, adult mice presented a specific visit of the target hole. Old, untreated wild-type and APP SDL mice showed a significantly decreased precision in their search pattern and DMSO treatment specifically improved the memory accuracy performance of old APP SDL mice compared to their untreated counterparts. Opposite (O) and target (T) holes. Chance level is indicated by the red line. All values are represented as mean ± S.E.M. *P < 0.05, **P < 0.01 and ***P < 0.001, versus target exit hole. £ P < 0.05, ££ P < 0.01 and £££ P < 0.001, versus chance level. (AeC) Adult untreated: wild-type (n ¼ 6) and APP SDL mice (n ¼ 7). Old treated and untreated: wild-type and APP SDL mice (n ¼ 7 mice/group). Repeated measures ANOVA followed by post-hoc Newman-Keuls multiple comparison test. (C) For chance level, Student's t-test. For detailed statistics see Supplementary Table 4. abolishing Ab-mediated neuronal hyperactivation in the hippocampus of APP SDL mice.
The spatial memory retrieval resulted in comparable neuronal activation between wild-type and APP SDL mice in all hippocampal and neocortical regions analyzed (Fig. 4B and C, Supplementary Table 5) suggesting that Ab-mediated alteration of neuronal activation was specific to baseline condition. DMSO treatment significantly reduced neuronal activation in the CA3 region of APP SDL mice but raised the level of neuronal activity in the CA1 region of wildtype mice compared to untreated mice from the same genotype (B, right) n ¼ 6e7 mice/group. *P < 0.05, **P < 0.01 and ***P < 0.001, wild-type versus APP SDL mice, same experimental condition. #P < 0.05, ##P < 0.01 and ###P < 0.001, significantly decreased compared to untreated same genotype. (C) DMSO treatment modulates spatial memory retrieval-related c-fos positive cell density in a region and genotype-specific manner by decreasing c-fos density in the CA3 region of APP SDL mice, by increasing c-fos density in the CA1 region of wild-type mice and by inducing a significant difference between both genotypes in the LPar region. No significant effect occurred in the DG. Old treated and untreated wild-type and APP SDL mice (n ¼ 6e7 mice/group). All values are represented as mean ± S.E.M. *P < 0.05 and **P < 0.01, wild-type versus APP SDL , same experimental condition. #P < 0.05, significantly decreased and þ P < 0.05 significantly increased compared to untreated, same genotype. Factorial ANOVA followed by post-hoc Fisher's LSD for multiple comparisons. For detailed statistics see Supplementary Table 5. ( Fig. 4C, Supplementary Table 5 ). In the LPar, DMSO induced a significant difference in c-Fos expression between wild-type and APP SDL mice that was not apparent in untreated condition. No changes were induced by DMSO in the RSGc of mice from both genotypes (Fig. 4B, Supplementary Table 5 ). Therefore, chronic DMSO treatment modulates both basal and spatial memory retrieval induced neuronal activation in a region-and genotypespecific manner.
DMSO treatment restores olfactory sensitivity
Influence of chronic DMSO treatment on olfactory behavior was determined in old (17e18 M) wild-type and APP SDL male mice utilizing an odor habituation task (Fig. 5A) . Again, untreated adult (7e8 M) mice served as an additional control for the evaluation of the performance of old mice. No difference was observed in nose poke (NP) duration between the two genotypes of adult mice. However, all along the odor sampling period, NP duration of old APP SDL mice was significantly higher (Fig. 5B, Supplementary  Table 6 ), a difference abolished by DMSO treatment, which normalized NP duration to the level of age-matched wild-type mice and adult mice of the same genotype. In contrast, NP number was only increased in old wild-type mice, which did not differ any longer from the level of adult mice after DMSO treatment (Fig. 5C , Supplementary Table 6 ). We examined the investigation time during the first five NPs, as an indicator of odor habituation. Only old, untreated APP SDL mice displayed a delayed habituation, highlighted by the absence of a gradual decrease between the first and fourth NP duration. Interestingly, for the first three NPs, the olfactory performance of old APP SDL mice was normalized to the level of old wild-type mice by chronic DMSO (Fig. 5D , Supplementary Table 7 ), indicating that Ab-induced decreased olfactory habituation was attenuated by DMSO treatment.
DMSO treatment attenuates anxiety-related behavior
DMSO has been previously reported to display anxiolytic properties (Matheus et al., 1997) . Whether chronic DMSO treatment modulates anxiety-like behavior in old wild-type and APP SDL male mice was determined using the elevated-plus maze test. As before, untreated adult (7e8 M) mice served as reference control for the evaluation of the performance of old mice. Adult APP SDL mouse behavior was indistinguishable from wild-type mice in terms of distance travelled (Fig. 6A, Supplementary Table 8 ), number of entries (Fig. 6B, Supplementary Table 8) , percentage of entries in open arms (Fig. 6C, Supplementary Table 8 ) and percentage of time spent in open arms (Fig. 6D, Supplementary  Table 8 ). In contrast, old APP SDL mice significantly differed from old wild-type mice with respect to the distance travelled, the number of entries and the percentage of time spent in open arms, indicating a genotype-specific effect of aging on anxiety-like behavior. DMSO treatment induced a significant decrease of the number of entries for old wild-type mice and abolished the differences in the percentage of entries and time spent in open arms for APP SDL mice, which furthermore did not differ from chance level anymore. In contrast, time spent in open arms by old treated wildtype mice was significantly lower than chance level after DMSO treatment. These data suggest that the age-related increase of anxiety-like behavior in old APP SDL animals is attenuated by chronic DMSO treatment. On the opposite, DMSO treatment may display anxiogenic effects in old wild-type animals.
Discussion
DMSO has already been tested in several clinical trials more than 3 decades ago (Swanson, 1985) , and some of its biological activities have shown to be beneficial against various pathologies, such as dermatologic, urinary, pain or inflammatory disorders (Santos et al., 2003; Yu and Quinn, 1994) . Nevertheless the effect on the CNS structure and function had been remarkably ignored. In the present study, we demonstrate for the first time that chronic treatment with low, non-toxic DMSO dose displays region-and genotype-specific modulating actions on (i) hippocampal spine density, both ex vivo and in vivo, (ii) hippocampal-dependent and independent behavior, and (iii) neuronal activity, abolishing the differences observed between old APP SDL and wild-type male mice.
After intravenous and cutaneous application, DMSO shows a fast (within few hours) and approximately equal distribution in soft tissues, including brain. There is no evidence for accumulation of DMSO in the brain tissue and the elimination occurs within 12e36 h in experimental animals (Denko et al., 1967; Kolb et al., 1967) . However at high doses, DMSO presents diuretic properties (Suominen and Uusi-Penttila, 1968) , resulting in altered water consumption. Here, we have shown that chronic treatment with 1% DMSO neither modified daily water intake nor resulted in a dramatic change in organ weight, suggesting that 14 days of chronic treatment with 1% DMSO is generally not harmful for old mice. Low concentrations of DMSO have been shown to induce neurochemical (Matsumoto et al., 1985; Nasrallah et al., 2008; Obregon et al., 2005) and neuroelectrical changes (Lu and Mattson, 2001; Nakahiro et al., 1992; Tamagnini et al., 2014; Tsvyetlynska et al., 2005) , which consequently might result in plastic synaptic changes. Yet, to date structural changes in synaptic connectivity and their potential effect on behavior after systemic, chronic administration of DMSO were barely investigated.
Under physiological conditions, naturally secreted Ab peptides are known to regulate CNS function (Cirrito et al., 2005) . However, increased concentrations of soluble Ab (Wei et al., 2010) cause a marked decrease in spine density, which has been shown to be reversible (Smith et al., 2009 ). In our transgenic APP SDL mouse model, Ab resulted in a region-specific decrease of spine density on hippocampal neurons, in both organotypic slice cultures and in the brain, which was region-specifically counteracted by DMSO treatment. The intrinsic properties of neurons from these hippocampal subfields have been reported to differ in many aspects, including their NMDA and AMPA receptor content (Martens and Wree, 2001) , determining their sensitivity to Ca 2þ (Grishin et al., 2004) . Low DMSO dose has been shown to decrease Ca 2þ responses to glutamate, protecting hippocampal neurons from excitotoxic death (Lu and Mattson, 2001 ). We and others have shown that Ab-induced spine pathology involves NMDA receptor activation . Obtaining memory facilitating effects from an NMDA receptor antagonist may sound counterintuitive. However, improvement of memory performances by a NMDA receptor antagonist had been repeatedly shown in a wide range of disease models associated with memory disturbances (Marszalek-Grabska et al., 2016; Scholtzova et al., 2008) but also in non-diseased animals depending on the type of task, timing and dose provided (Mondadori and Weiskrantz, 1993; Puma and Bizot, 1998 ). Here we provide evidence suggesting that spine density modulation by DMSO is indeed achieved by its action on NMDA receptors, since an NMDAR antagonist, MK-801 recapitulated the effect of DMSO on spine density in organotypic slice cultures. Modulation of cell signaling by low concentrations of DMSO could also explain the differential regulation of neuronal activation in various brain regions, as determined by the c-Fos expression analysis. The most obvious examples include the subregions that elicit Ab-related hyperactivity. These data are consistent with recent work reporting that changes in neuronal activation occur independently of plaque deposition due to the presence of soluble Ab (Busche et al., 2012) . Moreover, excessive hippocampal activation has also been reported in cognitively impaired individuals at high risk to convert to AD (Dickerson et al., 2005) . Interestingly, pharmacological reduction of hippocampal hyperactivation in such individuals improved their memory performances (Bakker et al., 2012) . Here we showed that DMSO exerts a beneficial influence through the normalization of this pathological trait. It should however be noticed that DMSO is a very interesting molecule: it contains a hydrophilic and a hydrophobic part, and in the same time it is a dipole molecule with polar character. Already early studies described DMSO being effective in reversibly altering the configuration of proteins (Rammler and Zaffaroni, 1967) . Later on in silico molecular dynamics analysis as well as cell studies pointed to a concentration dependent membrane altering effect of DMSO (de Progressive decrease in the duration of the first five nose pokes occurs for adult mice, indicating habituation to new odorants. Odor habituation of old untreated APP SDL mice significantly differs from the performance of adult mice from the same genotype, and from old untreated wild-type mice, whereas DMSO treatment significantly attenuates olfactory deficits of APP SDL mice. Adult wild-type (n ¼ 6) and APP SDL mice (n ¼ 7), old wild-type and APP SDL mice (n ¼ 6e7 mice/group). All values are represented as mean ± S.E.M. (B) *P < 0.05, **P < 0.01, wild-type versus APP SDL , same experimental condition. ##P < 0.01 significantly decreased compared to untreated, same genotype. (D) *P < 0.05, **P < 0.01 and ***P < 0.001, versus first nose poke. (BeD) ¤ P < 0.05, ¤¤ P < 0.01 and ¤¤¤ P < 0.001, versus adult animal of the same genotype. Tables 6 and 7 . Menorval et al., 2012; Gurtovenko and Anwar, 2007) . DMSO has therefore pleiotropic actions, implying that part of the beneficial effects might also be attributed to a more global influence of this compound. Previously, high DMSO concentrations have been proposed to alter Ab aggregation (Shen and Murphy, 1995) . However, our investigation of the oligomeric Ab (oAb) amount in both, OB and hippocampus of APP SDL mice showed no difference due to DMSO used at low dose (Fig. 7, Supplementary Table 9 ), indicating that the beneficial effect of DMSO is not caused by decreased levels of oAb and confirming that the mode of action of DMSO is highly concentration dependant.
DMSO-mediated changes on spines are likely to affect synaptic plasticity underlying hippocampal-dependent learning and memory. Indeed, age-related decrease in spatial memory accuracy was attenuated with 1% DMSO treatment for APP SDL mice. However, DMSO might modulate also hippocampal-independent behavior. Altered olfactory function has been associated with amyloidosisrelated pathologies and might represent an informative biomarker to diagnose the earliest stage of neuropathologies, such as AD or PD (Alvarado-Martinez et al., 2013; Jimbo et al., 2011; Wesson et al., 2010) . This has been further confirmed by a very recent study in humans, where it has been suggested that olfactory tests have the potential for screening for MCI and MCI that is likely to progress to AD (Roberts et al., 2015) . Here, we found that old APP SDL mice displayed decreased olfactory habituation compared to wild-type mice. Interestingly, chronic DMSO normalized APP SDL olfactory performances to the level of adult mice. Differences in anxiety-like behaviors between APP SDL and wild-type mice develop with aging. Consistent with previous work (Matheus et al., 1997) , DMSO treatment displayed a moderate anxiolytic effect in old APP SDL mice. Intriguingly, chronic DMSO appeared to be anxiogenic for old wild-type mice by mildly decreasing the time spent in open arms.
Conclusions
Currently, DMSO continues to be one of the most used vehicle in the evaluation of potential hydrophobic drug candidates in basic biological research. Our data highlight unexpected effects of systemic administration of chronic, low, non-toxic DMSO with a differential effect in wild-type and APP SDL mice. Thus, DMSO should be considered as a true bioactive compound whose mechanisms of action might be beneficial against some neurodegenerative conditions. Consequently, the effects of chronic DMSO on synaptic plasticity and behavior are important to be considered for the development of appropriate therapies for neurodegenerative diseases.
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